PARTNERING WITH TODAY’S BIOTECH INNNOVATORS
Chief Partnership Officer
Responsible for building, and maintaining relationships with key biotech partners. Develop and execute fundraising strategies for portfolio companies including but not limited to IPO listings.
Chief Scientific Officer
Communicate with the scientific members of the customers and partners. Coordinate with other members of their organization and scientific community.
Head of Drug Discovery & Development
Formulate and supervise the overall research & development strategy of the company including all phases of discovery, preclinical and early clinical development.
PhD, Genomics Data Scientist
Lead the team in the integration of genetics, computational biology, statistical data analysis, to discover drugs.
Computational Chemist
Lead the team in the design and development of AI-Enabled, Genomic-Driven Drug Discovery platform.
Molecular Biologist
Lead the research team that is responsible for conducting research, performing experiments, and analyzing data t
Ximyx Labs a data-driven Venture Studio focused on partnering with Biotech companies headquartered in US and EU. Ximyx Labs AI-Enabled Genomics-Driven platform focuses on drug discovery in the areas of oncology, rare diseases, infectious diseases, cardiology, neurology, metabolic, and other disease areas. The company generates revenue from its proprietary platform’s licensing and collaboration partnerships.
We focus on identifying the best “Scientific-Driven” biotech companies located in US and EU and creating new therapeutic paradigms for first-in-class programs with our Venture Studio Business Model.
Product Ideas: Venture studios create startups by incubating their own ideas or ideas from their partners. The studio's internal team builds a minimum viable product (MVP) and validates the idea by finding product/market fit and early customers.
Venture studios facilitate connections with potential partners, entrepreneurs, and investors, who offer ongoing support and resources to portfolio companies.
Our business model enables us to work effectively with partners worldwide. We support leading biotech companies who have not previously engaged in development in China and major Asian markets. Through balanced partnerships, both strategic and financial, we believe we can harness compelling science to bring better medicines to patients.
discovery platform is the convergence of multiple technological forces, including human genomics, deep learning, biological engineering, and translational medicine, that are enabling us to decipher biology.
discovery platform identifies novel, diverse and pharmacologically active therapeutic antibodies . By analyzing the target's structure and dynamics, the platform can predict antibody-antigen interactions, identify potential binding sites, and help design optimized antibody variants with higher affinity and specificity.
Platform addresses challenges throughout the CGT value chain by enabling navigation and analysis of large and complex data, automating and speeding up manual and error-prone processes and workflow, and allowing trials of various options and conditions in virtual settings simultaneously.
We are a Artificial Intelligence (AI) Drug Design and Discovery Research and Development company, applying Deep Learning (DL) and Convolutional Graph Networks (CGNs) with , which utilize either supervised training procedures that is the foundation of its proprietary Computational Drug Design and Discovery Platforms
Mosenda is a fundraising consulting organization experienced in supporting companies in North America, Europe and Asia. The organization works to guide clients towards strategic alliances with investors and partners that lead to growth and investment in client companies
Billy Wong concentrates his practice on capital markets, mergers and acquisitions, corporate restructuring, private equity investments, and venture capital financing